JPS63503241A - Improved laboratory diagnostic methods especially for infections caused by HTLV3 viruses - Google Patents
Improved laboratory diagnostic methods especially for infections caused by HTLV3 virusesInfo
- Publication number
- JPS63503241A JPS63503241A JP61506160A JP50616086A JPS63503241A JP S63503241 A JPS63503241 A JP S63503241A JP 61506160 A JP61506160 A JP 61506160A JP 50616086 A JP50616086 A JP 50616086A JP S63503241 A JPS63503241 A JP S63503241A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibodies
- incubation
- antibody
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 本発明はHTLV I[ウィルスによってひき起こされた感染の実験室的改良診 断方法、さらに詳しくは公知方法に比してより大きな特異性を有し、かつ該感染 の第1段階において典型的なIgMクラスの抗体の存在を明らかにすることを可 能とする方法を提供する。[Detailed description of the invention] The present invention provides improved laboratory diagnostics for infections caused by HTLV I [virus]. More specifically, it has greater specificity than known methods, and In the first step, it is possible to reveal the presence of typical IgM class antibodies. provide a method to enable
現在用いられている血清学的診断方法は血液試料の試験によりある種の感染につ いて特異的抗体を調査することに基礎をおくものである。Currently used serological diagnostic methods detect certain infections by testing blood samples. It is based on the investigation of specific antibodies.
抗体は免疫グロブリン、すなわちそれらが作用する抗原に完全に適合するような 構造の蛋白質であることはよく知られている。Antibodies are immunoglobulins, meaning molecules that are perfectly matched to the antigen they act on. It is well known that it is a structural protein.
(抗原決定基に対して特異的な)各種抗体は、同様の特異性を有するが、略語: IgG、IgA、 IgD、IgE。Various antibodies (specific for antigenic determinants) have similar specificities, but the abbreviations: IgG, IgA, IgD, IgE.
IgMによって区別される5つのクラスに分けられることに基づき、異なる免疫 化学特性を有する免疫グロブリンよりなる。Based on the division into five classes distinguished by IgM, different immune systems Consists of immunoglobulins with chemical properties.
かくして、同様の特異性を有する異なるクラスの抗体があり;従って、IgMお よびIgGクラスの抗体は共存することができ、共にHTLV I[ウィルスに 対して作用する。Thus, there are different classes of antibodies with similar specificities; therefore, IgM and Antibodies of the HTLV and IgG classes can coexist, and both It acts against.
また、各クラスの抗体は動物に注射されると同一クラスの抗体の形成をひき起こ すことも公知である。Also, each class of antibodies causes the formation of antibodies of the same class when injected into animals. It is also known that
例えば、ヒ) IgG免疫グロブリンが動物に注射されると、それらはヒ) I gGがいかなる特異性を有するにせよ、ヒ) IgGに対し、かつそれらに対し てのみ抗−抗体作用を生じる。For example, when human) IgG immunoglobulins are injected into animals, they become human) Whatever the specificity of IgG, H) for and against IgG. Anti-antibody effects occur only when antibodies are used.
前記した如く、該感染の血清学的診断は、また、患者の血液中に存在する関連抗 体の調査よりなる。As mentioned above, serological diagnosis of the infection also depends on the presence of relevant antibodies in the patient's blood. It consists of an examination of the body.
現在用いられている方法の1つは、公知の抗原を含有する化合物を調製し、それ を固体媒体、例えば小さなポリスチレン球に固定することを提供するものである 。One method currently used is to prepare a compound containing a known antigen and to a solid medium, such as a small polystyrene sphere. .
次いで、試験中の患者から採取した血液試料を抗原でコートした小球と反応させ る。Blood samples taken from patients in the study are then reacted with the antigen-coated globules. Ru.
明確な感染についての特異的抗体が血液中に存在すると、この段階中に、小球上 に存在しかつその上に固定された抗原によってそれらは捕獲される。During this stage, when specific antibodies for a definite infection are present in the blood, They are captured by the antigen present on and immobilized on.
この時点で、小球は共役抗−抗体と(すなわち、通常免疫化ヤギから得られ、か つペルオキシダーゼ、ホスファターゼなどの如き特異的酵素と結合した抗−抗体 または抗−免疫グロブリンのいずれかよりなる反応体と)反応し;関連媒体のひ き続いての添加は、抗体の存在、従って感染の状態を示す発色をひき起こす。At this point, the globules are coated with a conjugated anti-antibody (i.e. usually obtained from an immunized goat, Anti-antibodies conjugated to specific enzymes such as peroxidases, phosphatases, etc. or anti-immunoglobulin); the relevant medium Subsequent addition causes the development of a color indicating the presence of antibodies and thus the status of infection.
特異的抗体をそれ自身の抗原によって捕獲し、次いで抗−抗体によりその存在を 明らかにすることによって特異的抗体を決定することに基づくこの血清学的診断 方法は、他の方法に比し、非常に良好な感度を有するが、特異性は不十分である 。A specific antibody is captured by its own antigen and its presence is then detected by an anti-antibody. This serological diagnosis is based on determining specific antibodies by revealing The method has very good sensitivity compared to other methods, but specificity is insufficient .
より詳細には、HTLV I[ウィルスの場合、感染の第1段階を特徴づけるI gM抗体についての調査において最大の非特異性が生じる。現時点では、AID Sウィルス、I(TLV IIの場合、診断方法は関連するIgGクラス抗体に ついての調査に基づく。今日量も普及している技術の一方法を以下に記載する。More specifically, HTLV I [In the case of viruses, I which characterizes the first stage of infection] The greatest nonspecificity occurs in studies with gM antibodies. At present, A.I.D. In the case of S virus, I (TLV II), the diagnostic method is based on the relevant IgG class antibodies. Based on research on One method of technology that is widespread today is described below.
かかる場合において、6ミリ直径のポリスチレン球の表面に精製した抗原を固定 し、水蒸気加熱容器中に入れる。In such cases, purified antigens are immobilized on the surface of 6 mm diameter polystyrene spheres. and place it in a steam heating container.
非特異的反応を避けるために400倍まで希釈した後、試験血清をそれが球コー トと反応する容器中に入れる。After diluting up to 400 times to avoid non-specific reactions, the test serum was Place it in a container where it will react with the reaction mixture.
この段階では水浴の温度を40°に保持する。At this stage the water bath temperature is maintained at 40°.
インキュベーションの最後に、公知タイプの吸上げ−および押上げポンプ装置に よって小球を洗浄し、その後、あらかじめペルオキシダーゼと結合させた後、特 異的IgG群抗体を添加する。At the end of the incubation, a suction-and-up pump device of known type is used. Therefore, the globules are washed and then, after pre-binding with peroxidase, a special Add different IgG group antibodies.
第2のインキュベーションの最後に、もう−回洗浄し、もし存在すると抗−抗体 共役体に作用する媒体を添加する。At the end of the second incubation, wash one more time and remove the anti-antibody, if present. Add a medium to act on the conjugate.
抗−抗体共役体の存在はもしあると感染状態を示す発色によって指示される。The presence of anti-antibody conjugate, if present, is indicated by color development, which indicates infection status.
この方法によっては、試験血清をかなり希釈しても、部分的にはいくらかのIg G免疫グロブリンの非特異的吸収のため、誤った陽性判断が全く同様に得られる 。With this method, even if the test serum is significantly diluted, some Ig Due to nonspecific absorption of G immunoglobulin, false positive judgments are obtained in exactly the same way. .
加えて、非特異的陽性判断が1gM免疫グロブリンによってしばしば同様に得ら れるので、この種類の診断によっては、このクラスの免疫グロブリンの存在のみ を明らかにできる。In addition, nonspecific positive readings are often obtained with 1 gM immunoglobulin as well. Depending on this type of diagnosis, only the presence of this class of immunoglobulin can be detected. can be revealed.
1gM免疫グロブリンのみがHTLV I[ウィルス感染の(数カ月継続の)開 始期に形成されるので、現在公知の診断方法はこの第1段階中のかかる感染の存 在を検知するのを可能としない。Only 1 gM immunoglobulin was found to be effective against HTLV I [open viral infection (which lasted for several months)]. Currently known diagnostic methods do not detect the presence of such an infection during this first stage. It does not make it possible to detect the presence of
従って、(血液提供者の場合におけるごとく)伝染を防止するために、およびよ り適時に治療するために、第1段階においてできるだけ早く、確実にこの種の感 染を判定することを可能とする診断方法に対する大きな要求が存在する。Therefore, in order to prevent contagion (as in the case of blood donors) and Ensure that this type of sensation is detected as early as possible in the first stage in order to treat it in a timely manner. There is a great need for diagnostic methods that allow the determination of infection.
この目的のため、本発明は、以下の工程:a)特にHTLV I[を攻撃する抗 体を関連抗原と固相において結合させることによって該抗体を分離し;b)続い てそれを熱溶離し; C)同一タイプの抗原でコートした、または同一タイプの抗原で部分的にコート した第2の小球上のかく精製した抗体を第2のインキュベーションに付し; d)選択したクラスの抗−抗体と共に第3のインキュベーションを行い、続いて 検出を行う ことを特徴とするHTLV I[ウィルス感染の実験室的診断の改良方法を提供 するものである。To this end, the invention provides the following steps: a) Antibiotics that specifically attack HTLV I b) separating the antibody by binding the antibody with the relevant antigen in a solid phase; to elute it hot; C) coated with the same type of antigen or partially coated with the same type of antigen subjecting the thus purified antibody on the second globule to a second incubation; d) A third incubation with anti-antibodies of the selected class, followed by perform detection HTLV I [Provides an improved method for laboratory diagnosis of viral infection] characterized by It is something to do.
以下により本発明をさらに詳しく記載する。The invention will be described in more detail below.
実施例 HTLV I[の精製抗原で表面をコートした球も含有する容器中に試験血清2 00μ!またはそれ以上を入れる。Example Test serum 2 was placed in a container that also contained spheres whose surfaces were coated with purified antigen of HTLV I. 00μ! or more.
公知方法により行うのとは異なり、この場合は血清を希釈せず、インキュベーシ ョンは40°の温度で、まず180 rpmにおいて攪拌語中で45分間、次い で水浴中で15分間行う。Unlike the known methods, in this case the serum is not diluted and the incubation cycle is used. The process was carried out at a temperature of 40°, first for 45 minutes under stirring at 180 rpm, then for 15 minutes in a water bath.
インキュベーションの最後に、球を通常の洗液で洗浄し、ある量のヤギ血清と共 にリン酸緩衝液よりなる希釈剤250μlを添加する。At the end of the incubation, the spheres are washed with normal wash solution and mixed with an amount of goat serum. Add 250 μl of a diluent consisting of phosphate buffer to the solution.
水浴の温度を30分間、50°と58’の間とする。最適温度は30分間での5 6°であることが判明した。かかる温度において、各種の特異的免疫グロブリン はそれらの各抗原から分離し、非特異的抗体と共に各種の特異的抗体の溶離体が 緩衝液体中に得られる。The water bath temperature is between 50° and 58' for 30 minutes. The optimum temperature is 5 for 30 minutes. It turned out to be 6°. At such temperatures, various specific immunoglobulins are separated from each of those antigens, and eluates of various specific antibodies as well as non-specific antibodies are Obtained in buffer liquid.
溶離期の最後に、棟上に存在する抗原によって抗体が再び吸収される容器内温度 の低下を防ぐために、液体をすばやく吸上げる。At the end of the elution phase, the temperature inside the container at which the antibody is reabsorbed by the antigen present on the ridge Lift up liquid quickly to prevent drops.
次いで、精製した抗体を含む収集液体を、第1のものと同様に、同一抗原でコー トした第2の球を含有する第2の容器に入れる。The collected liquid containing purified antibodies is then coated with the same antigen as in the first one. into a second container containing a second rounded ball.
次いで、第3のインキュベーションを開始し、常に40°とし1時間行うが、そ の間に免疫グロブリンのみが棟上のHTLV IIIに対して特異的に作用する 。Then a third incubation is started, always at 40° for 1 hour, but after that During this period, only immunoglobulin acts specifically against HTLV III on the ridge. .
この工程の最後において、球を洗浄し、共役体200μlを容器に入れる。次い で、40’において2時間10分の間インキュベーションをさらに行い、その後 球を洗浄し、試験管に入れる。At the end of this step, the bulbs are washed and 200 μl of conjugate is placed in the container. next Further incubation was carried out for 2 hours and 10 minutes at 40', then Wash the bulb and place it in a test tube.
次いで0PD300μlを添加し、室温にて全体を再び30分間インキュベート する。Then add 300 μl of 0PD and incubate the whole again for 30 minutes at room temperature. do.
次いでIN硫酸1dを添加する。Then 1 d of IN sulfuric acid is added.
かく得られた試料の光学密度を測定することによって、所望の結果を得ることが できる。By measuring the optical density of the sample thus obtained, the desired result can be obtained. can.
この方法によってクラスIgGおよびIgMの抗体の存在が検知でき、それによ り病気のほとんど初期においてHTLV IIIウィルス感染を確実に診断する ことが可能となる。By this method the presence of antibodies of class IgG and IgM can be detected, thereby Reliably diagnose HTLV III virus infection almost at the early stage of the disease. becomes possible.
ここにペルオキシダーゼよりなる検知系は、ホスファターゼまたはβガラクトシ ダーゼなどの如き他の酵素に基づくことができ;別法として、抗−抗体を、ディ テクターとして用いるラジオアイソトープと結合させることができる。Here, the detection system consisting of peroxidase is phosphatase or β-galactosylate. can be based on other enzymes such as Dase; alternatively, anti-antibodies can be It can be combined with a radioisotope used as a protector.
56冒こおける加熱によって抗体を溶離することよりなる方法は、赤血球からそ れらが攻撃される抗体を分離し、次いで抗体を溶離物中で精製して特異性を評価 し、およびいずれの血液系もしくは群に対してそれらが作用するかを判定する免 疫血液学の分野においてすでに公知であることをさらに指摘しておこう。56 A method consisting of eluting antibodies by heating in a isolate the antibodies that are attacked and then purify the antibodies in the eluate to assess specificity. immunology to determine which blood systems or groups they act on. Let us further point out what is already known in the field of epidemiological hematology.
それとは異なり、本発明の場合は、公知抗原によって捕獲された試験抗体を前記 と同一種類の他の精製抗原と反応させた後、最大限特異的に同一性を証明するた めにそれらを溶離するので、該方法は逆に適用される。In contrast, in the present invention, a test antibody captured by a known antigen is and other purified antigens of the same type, in order to demonstrate identity with maximum specificity. The method is applied in reverse so that they are eluted in order to elute them.
従って、本発明の特徴点は、同一の関連抗原によって捕獲された抗体の抗原の溶 離を行う点、および各共役体の添加前に、かく精製した抗体をひき続いて抗原の 第2層に固定することである。Therefore, a feature of the present invention is that antigen dissolution of antibodies captured by the same related antigen At the point of separation and prior to the addition of each conjugate, the thus purified antibody is subsequently incubated with the antigen. It is fixed to the second layer.
当業者ならば、要すれば、変法および変形を提供できるが、それらは本発明の範 囲内のものである。Those skilled in the art will be able to provide modifications and variations, if desired, which do not fall within the scope of the invention. It is within the range.
閑静!1審報告 ANNEX To ^KE INTERNAτ工○NAL 5EARCHREP ORT Oよ1quiet! First trial report ANNEX To ^KE INTERNAτ 工○NAL 5EARCHREP ORT Oyo1
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT22941A/85 | 1985-11-21 | ||
IT8522941A IT1214642B (en) | 1985-11-21 | 1985-11-21 | IMPROVED PROCEDURE FOR LABORATORY DIAGNOSIS OF INFECTIONS IN PARTICULAR D AVIRUSHTLV III. |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63503241A true JPS63503241A (en) | 1988-11-24 |
Family
ID=11202122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61506160A Pending JPS63503241A (en) | 1985-11-21 | 1986-11-20 | Improved laboratory diagnostic methods especially for infections caused by HTLV3 viruses |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0289493A1 (en) |
JP (1) | JPS63503241A (en) |
AU (1) | AU6732587A (en) |
IT (1) | IT1214642B (en) |
PL (1) | PL262516A1 (en) |
PT (1) | PT83787B (en) |
WO (1) | WO1987003375A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5268299A (en) * | 1988-04-14 | 1993-12-07 | Eastman Kodak Company | Diluent composition useful in the detection of antibodies in assays |
US5077198A (en) * | 1988-04-14 | 1991-12-31 | Eastman Kodak Company | Diagnostic kit and method for rapid detection of antibodies |
US5759774A (en) * | 1988-05-18 | 1998-06-02 | Cobe Laboratories, Inc. | Method of detecting circulating antibody types using dried or lyophilized cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5931453A (en) * | 1982-07-14 | 1984-02-20 | Fujirebio Inc | Measuring method of syphilis antibody |
EP0136798A3 (en) * | 1983-08-25 | 1986-02-19 | Biotech Research Laboratories Inc. | Titre plate and assay kit for detection of antibodies in human serum and their production and use |
CA1247005A (en) * | 1984-04-23 | 1988-12-20 | Robert C. Gallo | Isolation of protein of htlv-iii, serological detection of antibodies to htlv-iii in sera of patients with aids and pre-aids conditions, and detection of htlv-iii infection by immuno-assays using htlv-iii and its proteins |
-
1985
- 1985-11-21 IT IT8522941A patent/IT1214642B/en active
-
1986
- 1986-11-20 WO PCT/IT1986/000084 patent/WO1987003375A1/en not_active Application Discontinuation
- 1986-11-20 JP JP61506160A patent/JPS63503241A/en active Pending
- 1986-11-20 AU AU67325/87A patent/AU6732587A/en not_active Abandoned
- 1986-11-20 EP EP86906919A patent/EP0289493A1/en not_active Withdrawn
- 1986-11-21 PT PT83787A patent/PT83787B/en unknown
- 1986-11-21 PL PL1986262516A patent/PL262516A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PT83787A (en) | 1986-12-01 |
PT83787B (en) | 1988-02-22 |
EP0289493A1 (en) | 1988-11-09 |
WO1987003375A1 (en) | 1987-06-04 |
PL262516A1 (en) | 1987-12-14 |
AU6732587A (en) | 1987-07-01 |
IT1214642B (en) | 1990-01-18 |
IT8522941A0 (en) | 1985-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4294817A (en) | Method of fluoro immunoassay | |
US4322495A (en) | Immunoassay | |
US4894347A (en) | Erythrocyte agglutination assay | |
JPH0239747B2 (en) | ||
JPH05264553A (en) | Antigen prepared for detecting helicobacter pyroly | |
CA1146067A (en) | Solid phase immunoassay with labelled anti-hapten antibody | |
AU757629B2 (en) | Methods for assaying antibody and device for assaying antibody | |
US4642285A (en) | Sandwich EIA for antigen | |
US3992517A (en) | Detection of hepatitis B surface antigen by latex agglutination | |
CN109239326A (en) | Based on the micro-fluidic immuno-chip analysis method of magnetic particle nano enzyme and application | |
JP3186831B2 (en) | Aggregation complex as blood group reagent | |
Attallah et al. | Rapid detection of a Schistosoma mansoni circulating antigen excreted in urine of infected individuals by using a monoclonal antibody | |
JPS63503241A (en) | Improved laboratory diagnostic methods especially for infections caused by HTLV3 viruses | |
US4288426A (en) | Serological test for syphilis | |
EP0301141A1 (en) | Solid phase enzyme immunoassay test apparatus and process for detecting antibodies | |
JPS6316266A (en) | Reagent composition for measurement of autoantibody | |
WO1990015328A1 (en) | Improved immunoassay | |
JPH02503951A (en) | assay | |
AU784387B2 (en) | Immunoassay of human medullasin and diagnosis of multiple sclerosis using the same | |
WO1990007114A1 (en) | Solid phase immuno-assay with labelled conjugate | |
EP0291479A1 (en) | Immunoassay method for the diagnosis of chlamydia infection | |
JPS62168052A (en) | Immunity test of antibody to htlv-iii pair | |
Choy et al. | A comparison of immunological methods for the detection of Trichinella spiralis antigen | |
JP3283327B2 (en) | Solid-phase immunoassay | |
EP0080108A1 (en) | Diagnostic reagent and use thereof |